PHR 250117 22.50P (PHR250117P22500) Stock Options, News & Quotes

0.50
0.000.00%

15min DelayTrading Dec 17 15:07 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Stock_Drift

Sep 15 13:27

$Phreesia (PHR.US)$

Moomoo AI

Dec 19, 2023 01:57

Investor confidence, reflected in a high P/S ratio and increasing share prices despite fluctuations, suggests anticipated persistent growth in Phreesia. Caution advised over sole reliance on price-to-sales ratios for investment decisions.

Phreesia, Inc.'s (NYSE:PHR) P/S Is Still On The Mark Following 43% Share Price Bounce

Moomoo Breakfast US

Jun 3, 2022 07:29

Columns Today's pre-market stock movers: TSLA, CHGG, OKTA, TPTX and more

Gainers:
• $Okta (OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo (STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics (TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals (AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...

Analysts Notebook

Apr 14, 2022 06:26

Columns Top upgrades and downgrades on 4/14

Upgrades
• $CDW Corp (CDW.US)$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $Corteva (CTVA.US)$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $CoreCivic, Inc. (CXW.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $Delta Air Lines (DAL.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $H.B. Fuller (FUL.US)$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Huntington Ingalls Industries (HII.US)$ : Cowen U...

Moomoo Breakfast US

Mar 31, 2022 07:53

Columns Today's pre-market stock movers: CLVS, PATH, DARE and more

Gainers:
• $Clovis Oncology (CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience (DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology (KULR.US)$ +9.5% (secured a battery sa...